文献速递脑血管病

阿替普酶用于发病时间不明的慢性肾脏病卒中患者:个体参与者数据的汇总分析

Alteplase for Stroke With Unknown Onset Time in Chronic Kidney Disease: A Pooled Analysis of Individual Participant Data.
PubMed 文献 · Stroke · 2022-08-23

该研究基于EOS试验协作的个体患者数据库,纳入688例发病时间不明的急性缺血性卒中患者,其中慢性肾脏病(CKD)146例(21%)。阿替普酶治疗与良好功能结局的较高比值相关,且CKD未改变治疗效果(交互作用P=0.834);CKD患者中阿替普酶组与对照组良好结局分别为46%与36%(校正比值比1.19,95%CI 0.55-2.58)。

要点

  • 在发病时间不明的卒中患者中,CKD未改变阿替普酶的治疗效果(交互作用P=0.834)。
  • CKD患者中阿替普酶组良好结局46% vs 对照组36%,校正比值比1.19(95%CI 0.55-2.58)。
  • CKD患者中症状性颅内出血阿替普酶组3% vs 对照组0%(P=0.133),90天死亡4% vs 3%(P=0.539)。

核心结论

  • 本分析表明,在发病时间不明的卒中患者中,阿替普酶的获益在有和无CKD的患者之间无差异,但统计学效能不足以确认亚组中的疗效。
  • 本研究仅适用于轻至中度或透析前CKD。

研究设计与样本

  • 基于EOS试验协作的个体患者水平数据库,纳入比较静脉溶栓与安慰剂/标准治疗的随机对照试验。
  • 共688例发病时间不明的急性卒中患者有基线肾功能数据,其中CKD 146例(21%),包括阿替普酶组69/351例和安慰剂/标准治疗组77/337例。
  • CKD定义为基线估算肾小球滤过率<60 ml/min/1.73m2,采用混合效应逻辑回归分析评估治疗效果。

主要发现

  • 总体而言,阿替普酶治疗与良好结局的较高比值相关,且CKD未改变治疗效果(交互作用P=0.834)。
  • CKD患者中,阿替普酶组31/69例(46%) vs 对照组28/77例(36%)达到良好结局(校正比值比1.19,95%CI 0.55-2.58)。
  • CKD患者中,症状性颅内出血阿替普酶组2例(3%) vs 对照组0例(P=0.133)。
  • 90天死亡阿替普酶组3例(4%) vs 对照组2例(3%)(P=0.539)。

关键数值与推荐

  • 良好结局定义为90天改良Rankin量表评分0至1分。
  • CKD定义为基线估算肾小球滤过率<60 ml/min/1.73m2。
  • 安全性结局为22至36小时症状性颅内出血和90天死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 统计学效能不足以确认亚组中的疗效。
  • 本研究仅适用于轻至中度或透析前CKD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although chronic kidney disease (CKD) is associated with worse stroke outcomes, data regarding the influence of CKD on intravenous thrombolysis outcomes are scarce. We sought to assess the efficacy and safety of intravenous thrombolysis for acute ischemic stroke with unknown onset time in patients with CKD. METHODS: Patients with an acute stroke of unknown onset time from the EOS trials (Evaluation of Unknown Onset Stroke Thrombolysis) collaboration were evaluated using an individual patient-level database of randomized controlled trials comparing intravenous thrombolysis with placebo/standard treatment. CKD was defined as baseline estimated glomerular filtration rate of <60 ml/min/1.73m2 Mixed-effect logistic-regression analysis was performed to evaluate treatment effects. A favorable outcome was defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes were symptomatic intracranial hemorrhage at 22 to 36 hours and 90-day mortality. RESULTS: Baseline data on renal function were available for 688 of 843 patients. Of these, CKD was present in 146 (21%), including 69 of 351 patients receiving alteplase and 77 of 337 patients receiving placebo/standard treatment. Overall, treatment with alteplase was associated with higher odds of favorable outcome, and CKD did not modify the treatment effect (Pinteraction=0.834). A favorable outcome was observed in 31 of 69 (46%) patients with CKD in the alteplase group and in 28 of 77 (36%) patients with CKD in the control group (adjusted odds ratio, 1.19 [95% CI, 0.55-2.58]). Among patients with CKD, symptomatic intracranial hemorrhage occurred in 2 patients (3%) in the alteplase group but in none of the controls (P=0.133). At 90 days, death was reported in 3 patients (4%) in the alteplase group compared with 2 patients (3%) in the controls (P=0.539). CONCLUSIONS: The present analysis indicates that the benefit of alteplase does not differ between stroke patients with unknown onset time with and without CKD, although the statistical power was lacking to confirm the efficacy in subgroups. This study only applies to mild-to-moderate or predialysis CKD.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Miwa K, Koga M, Jensen M, et al. Alteplase for Stroke With Unknown Onset Time in Chronic Kidney Disease: A Pooled Analysis of Individual Participant Data. Stroke. 2022. PMID: 35997023. doi:10.1161/STROKEAHA.122.039086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。